{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341187","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2026-08-10T11:00:07+00:00","discovered_at":"2026-08-10T11:05:00.366873+00:00","generated_at":"2026-08-10T11:06:21.495640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru reports Q3 FY2026 net loss $7.0M; PLATEAU trial fully enrolled with 239 patients","bullets":["Q3 net loss $7.0M ($0.30/share) vs $7.3M ($0.50/share) prior year; operating loss $7.7M.","Phase 2b PLATEAU fully enrolled with 239 patients (target 200); interim analysis Q1 2027, final topline Q4 2027.","USPTO notice of allowance for enobosarm+semaglutide patent; protection until at least Oct 2044.","Clinical supply agreement with Novo Nordisk for PLATEAU trial announced June 2026.","Cash $23.9M at June 30, 2026 vs $15.8M at Sept 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341187","json":"https://secwatch.observer/filing/0001193125-26-341187.json","markdown":"https://secwatch.observer/filing/0001193125-26-341187.md","text":"https://secwatch.observer/filing/0001193125-26-341187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/0001193125-26-341187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:06:21.495640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}